Efficacy and safety of anti-TNF-α therapy combined with cyclosporine a in patients with rheumatoid arthritis and concomitant hepatitis C virus infection

C. Giannitti, M. Benucci, R. Caporali, S. Manganelli, F. Bellisai, G. D. Sebastiani, Mauro Galeazzi

Research output: Contribution to journalArticle

Abstract

This study further expands our previous observation demonstrating the usefulness of combination therapy of anti-TNF-alpha and Cyclosporine A in the treatment of rheumatoid arthritis and concurrent hepatitis C virus infection, as well its efficacy and safety in controlling HCV viremia and liver toxicity. Seven patients were included in the study; transaminase levels remained unchanged, HCV RNA serum levels decreased significantly and DAS 28 significantly improved after twelve month follow-up. No side effects were registered.

Original languageEnglish
Pages (from-to)543-546
Number of pages4
JournalInternational Journal of Immunopathology and Pharmacology
Volume22
Issue number2
Publication statusPublished - Apr 2009

Fingerprint

amsonic acid
Virus Diseases
Hepacivirus
Cyclosporine
Rheumatoid Arthritis
Safety
Viremia
Transaminases
Tumor Necrosis Factor-alpha
Observation
RNA
Liver
Therapeutics
Serum

Keywords

  • Anti TNF- α
  • CsA
  • HCV
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Efficacy and safety of anti-TNF-α therapy combined with cyclosporine a in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. / Giannitti, C.; Benucci, M.; Caporali, R.; Manganelli, S.; Bellisai, F.; Sebastiani, G. D.; Galeazzi, Mauro.

In: International Journal of Immunopathology and Pharmacology, Vol. 22, No. 2, 04.2009, p. 543-546.

Research output: Contribution to journalArticle

@article{036918d4eb69411e856d62af039d9fd4,
title = "Efficacy and safety of anti-TNF-α therapy combined with cyclosporine a in patients with rheumatoid arthritis and concomitant hepatitis C virus infection",
abstract = "This study further expands our previous observation demonstrating the usefulness of combination therapy of anti-TNF-alpha and Cyclosporine A in the treatment of rheumatoid arthritis and concurrent hepatitis C virus infection, as well its efficacy and safety in controlling HCV viremia and liver toxicity. Seven patients were included in the study; transaminase levels remained unchanged, HCV RNA serum levels decreased significantly and DAS 28 significantly improved after twelve month follow-up. No side effects were registered.",
keywords = "Anti TNF- α, CsA, HCV, Rheumatoid arthritis",
author = "C. Giannitti and M. Benucci and R. Caporali and S. Manganelli and F. Bellisai and Sebastiani, {G. D.} and Mauro Galeazzi",
year = "2009",
month = "4",
language = "English",
volume = "22",
pages = "543--546",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of anti-TNF-α therapy combined with cyclosporine a in patients with rheumatoid arthritis and concomitant hepatitis C virus infection

AU - Giannitti, C.

AU - Benucci, M.

AU - Caporali, R.

AU - Manganelli, S.

AU - Bellisai, F.

AU - Sebastiani, G. D.

AU - Galeazzi, Mauro

PY - 2009/4

Y1 - 2009/4

N2 - This study further expands our previous observation demonstrating the usefulness of combination therapy of anti-TNF-alpha and Cyclosporine A in the treatment of rheumatoid arthritis and concurrent hepatitis C virus infection, as well its efficacy and safety in controlling HCV viremia and liver toxicity. Seven patients were included in the study; transaminase levels remained unchanged, HCV RNA serum levels decreased significantly and DAS 28 significantly improved after twelve month follow-up. No side effects were registered.

AB - This study further expands our previous observation demonstrating the usefulness of combination therapy of anti-TNF-alpha and Cyclosporine A in the treatment of rheumatoid arthritis and concurrent hepatitis C virus infection, as well its efficacy and safety in controlling HCV viremia and liver toxicity. Seven patients were included in the study; transaminase levels remained unchanged, HCV RNA serum levels decreased significantly and DAS 28 significantly improved after twelve month follow-up. No side effects were registered.

KW - Anti TNF- α

KW - CsA

KW - HCV

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=67650477221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650477221&partnerID=8YFLogxK

M3 - Article

C2 - 19505408

AN - SCOPUS:67650477221

VL - 22

SP - 543

EP - 546

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 2

ER -